Castleman's disease: Difference between revisions

Jump to navigation Jump to search
Line 101: Line 101:
* [[Lymph node]] [[biopsy]] is used as a differentiating tool in the diagnosis of Castleman's disease.  It is used to differentiate Castleman's from [[lymphoma]].
* [[Lymph node]] [[biopsy]] is used as a differentiating tool in the diagnosis of Castleman's disease.  It is used to differentiate Castleman's from [[lymphoma]].
* Variants of Castleman's disease can also be differentiated using biopsy.
* Variants of Castleman's disease can also be differentiated using biopsy.
{| align="center"
!
|-valign="top"
| [[Image:Castleman_disease_-_hyaline_vascular_variant.jpg|thumb|Micrograph of Castleman's disease, hyaline vascular variant, exhibiting the characteristically expanded mantle zone and a radially penetrating sclerotic blood vessel ("lollipop" sign). H&E stain.]]
| [[Image:Castleman_disease_-_Plasma_cell_variant.jpg‎|thumb|Intermediate magnification micrograph of Castleman disease showing the characteristic expansion of the mantle zone, known as "onion skinning". H&E stain.]]
|}


==Treatment==
==Treatment==

Revision as of 13:46, 6 August 2012

WikiDoc Resources for Castleman's disease

Articles

Most recent articles on Castleman's disease

Most cited articles on Castleman's disease

Review articles on Castleman's disease

Articles on Castleman's disease in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Castleman's disease

Images of Castleman's disease

Photos of Castleman's disease

Podcasts & MP3s on Castleman's disease

Videos on Castleman's disease

Evidence Based Medicine

Cochrane Collaboration on Castleman's disease

Bandolier on Castleman's disease

TRIP on Castleman's disease

Clinical Trials

Ongoing Trials on Castleman's disease at Clinical Trials.gov

Trial results on Castleman's disease

Clinical Trials on Castleman's disease at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Castleman's disease

NICE Guidance on Castleman's disease

NHS PRODIGY Guidance

FDA on Castleman's disease

CDC on Castleman's disease

Books

Books on Castleman's disease

News

Castleman's disease in the news

Be alerted to news on Castleman's disease

News trends on Castleman's disease

Commentary

Blogs on Castleman's disease

Definitions

Definitions of Castleman's disease

Patient Resources / Community

Patient resources on Castleman's disease

Discussion groups on Castleman's disease

Patient Handouts on Castleman's disease

Directions to Hospitals Treating Castleman's disease

Risk calculators and risk factors for Castleman's disease

Healthcare Provider Resources

Symptoms of Castleman's disease

Causes & Risk Factors for Castleman's disease

Diagnostic studies for Castleman's disease

Treatment of Castleman's disease

Continuing Medical Education (CME)

CME Programs on Castleman's disease

International

Castleman's disease en Espanol

Castleman's disease en Francais

Business

Castleman's disease in the Marketplace

Patents on Castleman's disease

Experimental / Informatics

List of terms related to Castleman's disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Synonyms and keywords: Angiofollicular lymph node hyperplasia; lymphoid hamartoma

Overview

Castleman's disease is a rare disorder characterized by non-cancerous growths (tumors) that may develop in the lymph node tissue throughout the body. It involves hyperproliferation of certain B cells that often produce cytokines.

Historical Perspective

In 1954 Dr. Benjamin Castleman, a pathologist described an unusual histopathology of a lymph node in a patient with mediastinal mass.

Classification

2 types of classifications exist for Castleman's disease. They are:

  • Clinical and Radiologic classification:
    • Unicentric - single lymph node is involved, most commonly in the mediastinum or the mesentery.
    • Multicentric - wide spread involvement of lymph nodes and also liver and spleen in some cases
  • Histopathologic classification:
    • Hyaline vascular
    • Plasmacytic
    • Mixed cellularity - has features of both hyaline vascular type and plasmacytic type.

Pathophysiology

In all cases, Castleman's disease is likely due to hypersecretion of the cytokine IL-6. In KSHV positive tumors, this is most likely due to expression of the a virus-encoded cytokine, vIL-6, while KSHV negative tumors appear to be the result of over secretion of human IL-6.

Associated Conditions

Castleman's disease is sometimes associated with:

Causes

  • About 50% of Multicentric Castleman's disease (MCD) is caused by Kaposi's sarcoma-associated herpesvirus (KSHV), a gammaherpesvirus that is also the cause of Kaposi's sarcoma and primary effusion lymphoma, while the remainder of MCD are of unknown cause.
  • The form of MCD most closely associated with KSHV is the plasmacytic form of Castleman's disease while another pathologic form, the hyaline-vascular form, is generally negative for this virus.

Epidemiology and Demographics

Age

  • Average age of the patients with unicentric disease is 30 - 40 yrs
  • For multicentric disease it is 50 - 60 yrs

Gender

  • No gender differentiation is seen in the occurrence of the disease.

Risk Factors

  • HIV/AIDS can act as a risk factor for this disease. The course of the disease is worse in these patients.

Natural History, Complications and Prognosis

Complications

Prognosis

  • Prior to 1996 MCD carried a poor prognosis of about 2 years, due to autoimmune hemolytic anemia and non-Hodgkin's lymphoma which may arise as a result of proliferation of infected cells. The timing of diagnosis, with particular attention to the difficulty of determining the cause of B symptoms without a CT scan and lymph node biopsy, may impact significantly on the prognosis and risk of death. Left untreated, MCD usually gets worse and becomes increasingly difficult and unresponsive to current treatment regimens.
  • HIV patients with multicentric disease have a grave prognosis. They have a less favorable clinical course and tend to develop Kaposi sarcoma and even plasmablastic non-Hodgkin lymphoma.

Diagnosis

Symptoms

The most common 'B symptoms' of MCD are

Physical Examination

Vitals

Skin

Head

Abdomen

Laboratory Findings

Imaging

CT

  • To detect the enlarged lymph nodes in the chest, neck, abdomen, groin.
  • Enlargement of liver and spleen can also be detected.
  • Findings include:
    • Contrast enhancement
    • Homogenous
(A)Castleman's disease Preoperative CT scan of the abdomen showing a highly vascularized retroperitoneal tumor measuring 10 × 9.2 cm with intratumor calcifications. Right ureter dilatation (grade II), (coronal multiplanar reformation, MPR) (B) The same tumor in axial orientation. No other tumor localization in the abdomen nor enlarged lymph nodes were detected.

PET Scan

  • To diagnose the extent of involvement of the disease and to assess the effect of treatment.

Biopsy

  • Lymph node biopsy is used as a differentiating tool in the diagnosis of Castleman's disease. It is used to differentiate Castleman's from lymphoma.
  • Variants of Castleman's disease can also be differentiated using biopsy.
Micrograph of Castleman's disease, hyaline vascular variant, exhibiting the characteristically expanded mantle zone and a radially penetrating sclerotic blood vessel ("lollipop" sign). H&E stain.
Intermediate magnification micrograph of Castleman disease showing the characteristic expansion of the mantle zone, known as "onion skinning". H&E stain.

Treatment

Unicentric

In the Unicentric form of the disease, surgical resection is often curative,[1] [2] and the prognosis is excellent.

Multicentric

There is no standard therapy for MCD at the moment.

It is important to distinguish AIDS-related Multicentric Castleman’s disease from other forms of Multicentric Castleman’s disease. Treatment for the former can be focused upon the same protocols used for treating the underlying AIDS.[3]

Recent work with HIV-positive patients with KSHV-related MCD suggests that treatment with the antiherpesvirus drug ganciclovir or the antiCD20 B cell monoclonal antibody, rituximab, may markedly improve outcome. These drugs target and kill B cells via the B cell specific CD20 marker. Since B cells are required for the production of antibodies, the body's immune response is weakened whilst on treatment and the risk of further viral or bacterial infection is increased. Due to the uncommon nature of the condition there are not many large scale research studies from which standardized approaches to therapy may be drawn, and the extant case studies of individuals or small cohorts should be read with caution. As with many diseases, the patient's age, physical state and previous medical history with respect to infections may impact on the disease progression and outcome.

Use of tocilizumab has been proposed.[4]

Siltuximab, a monoclonal antibody that binds interleukin-6, is currently being investigated in a Phase II clinical trial.[5]

Other treatments for multicentric castleman disease include the following:

References

  1. name=pmid21934347
  2. Talarico F, Negri L, Iusco D, Corazza GG (2008). "Unicentric Castleman's disease in peripancreatic tissue: case report and review of the literature". G Chir. 29 (4): 141–4. PMID 18419976. Unknown parameter |month= ignored (help)
  3. Sprinz E, Jeffman M, Liedke P, Putten A, Schwartsmann G (2004). "Successful treatment of AIDS-related Castleman's disease following the administration of highly active antiretroviral therapy (HAART)". Ann. Oncol. 15 (2): 356–8. doi:10.1093/annonc/mdh066. PMID 14760135. Unknown parameter |month= ignored (help)
  4. Matsuyama M, Suzuki T, Tsuboi H; et al. (2007). "Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease" (– Scholar search). Intern. Med. 46 (11): 771–4. doi:10.2169/internalmedicine.46.6262. PMID 17541233.[dead link]
  5. A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease ClinalTrails.gov.
  6. http://www.mayoclinic.com/health/castleman-disease/DS01000/DSECTION=treatments-and-drugs
  • Aoki Y, Yarchoan R, Wyvill K, Okamoto S, Little RF, Tosato G. Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders. Blood 2001;97(7):2173-6.
  • Yarchoan R, Little RF. Immunosuppression-related malignancies. In: DeVita Jr. VT, Hellman S, Rosenberg SA, eds. Cancer, Principles and Practice of Oncology 6th Edition. Philadelphia: Lippincott Williams and Wilkins; 2001:2575-97.

de:Morbus Castleman

Template:WS